Results 51 to 60 of about 4,268 (199)

Comparing Approaches for Estimating Counterfactual HIV Incidence Among Populations With High Vulnerability to HIV in Lima, Peru: A Multi‐Study Comparative Analysis

Journal of the International AIDS Society, Volume 29, Issue 9, September 2026.
ABSTRACT Introduction The availability of highly efficacious HIV pre‐exposure prophylaxis (PrEP) makes it unethical or infeasible to conduct inactive/placebo‐controlled trials to evaluate new HIV prevention options. As a result, randomized active‐control non‐inferiority trials are typically employed; however, they require large sample sizes and ...
Fei Gao, Sayan Dasgupta, Siavash Pasalar, Qi Wang, Ricardo Alfaro, Delia Pinto‐Santini, Thiago S. Torres, Jorge Sanchez, Javier R. Lama, Valdilea G. Veloso, Michal Juraska, Robinson Cabello, Jorge O. Alarcon, Beatriz Grinsztejn, Carlos F. Caceres, James F. Rooney, Ann Duerr   +16 more
wiley   +1 more source

Matrix Approach Assessment of Cabotegravir Drug–Drug Interactions with OAT1/OAT3 Substrates and UGT1A1/UGT1A9 Inhibitors Using Physiologically-Based Pharmacokinetic Modeling

Pharmaceutics
Background/Objective: Cabotegravir (CAB), available as an oral tablet and as a long-acting (LA) nanosuspension for intramuscular injection, is approved as a combination therapy for the treatment, and as a monotherapy for the prevention, of HIV-1 ...
Helen Tracey, Simon T. Bate, Susan Ford, Parul Patel, Jackie Bloomer, Aarti Patel, Kunal S. Taskar   +6 more
doaj   +1 more source

Effect of a Peer Support Intervention for Oral Pre‐Exposure Prophylaxis Uptake and Adherence Among Adolescent Girls and Young Women at Risk of HIV Acquisition in Kampala, Uganda: A Randomized Controlled Trial

Journal of the International AIDS Society, Volume 29, Issue 9, September 2026.
ABSTRACT Introduction Daily oral pre‐exposure prophylaxis (PrEP) use remains low among adolescent girls and young women (AGYW). We evaluated whether a peer support intervention improved daily oral PrEP uptake and adherence among AGYW at high risk of HIV acquisition in Kampala, Uganda.
Yunia Mayanja, Andrew Abaasa, Kenneth Roger Katumba, Matthew Spinelli, Bernard Kikaire, Monica Gandhi, Kyriaki Kosidou, Anna Mia Ekstrom, Eugene Ruzagira   +8 more
wiley   +1 more source

In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents. [PDF]

, 2017
Long-acting injectable antiretrovirals represent a pharmacological alternative to oral formulations and an innovative clinical option to address adherence and reduce drug costs.
David J. Back, Charles Flexner, Flexner, C, Owen, A, Rajoli, RKR, Rannard, S, Siccardi, M, Marco Siccardi, Rajith K. R. Rajoli, Steve Rannard, Back, DJ, Andrew Owen, Meyers, CF, Caren Freel Meyers   +13 more
core   +1 more source

Long‐Acting Cabotegravir/Rilpivirine Reduces Immune‐Activation and ‐Senescence in People With HIV With CMV Co‐Infection

Immunology, Volume 179, Issue 1, Page 138-148, September 2026.
This study investigates the impact of switching to long‐acting (LA) injectable cabotegravir and rilpivirine (CAB/RPV‐LA) on immune‐activation and ‐senescence in people with HIV (PWH). Thirty‐seven PWH switching to CAB/RPV‐LA and nine continuing oral ART were analysed over 72 weeks. LA therapy led to significant reductions in activation T and senescence
Mariasilvia Guardiani, Eeva Tortellini, Anna Carraro, Maria Antonella Zingaropoli, Lorenzo Ansaldo, Alessandra Grimaldi, Serena Vita, Federica Dominelli, Fabio Mengoni, Caterina Pasquazzi, Ombretta Turriziani, Maria Rosa Ciardi, Vincenzo Vullo, Claudio Maria Mastroianni, Raffaella Marocco, Cosmo Del Borgo, Miriam Lichtner   +16 more
wiley   +1 more source

Targeting Human Immunodeficiency Virus Integrase Beyond the Active Site: The Discovery and Development of Allosteric Integrase Inhibitors

ChemMedChem, Volume 21, Issue 16, 27 August 2026.
Human immunodeficiency virus (HIV) allosteric integrase inhibitors (ALLINIs) offer a vital alternative to standard therapies by targeting noncatalytic sites. By inducing aberrant integrase multimerization, they disrupt viral maturation. This review explores their medicinal chemistry evolution, detailing structural insights, structure–activity ...
Francesco Saccoliti, Elisa Patacchini, Emanuele Cara, Laura Zarbo, Antonella Messore, Aurora Albano, Giuseppe Ruggieri, Valentina Noemi Madia, Luigi Scipione, Roberta Costi, Roberto Di Santo   +10 more
wiley   +1 more source

Exploring perceptions and preferences for PrEP choice and of an mHealth intervention: insights from the ImPrEP CAB‐Brasil study

Journal of the International AIDS Society
Introduction Although the efficacy of long‐acting injectable cabotegravir (CAB‐LA) for pre‐exposure prophylaxis (PrEP) is well‐known from clinical trials, research is needed to guide effective strategies for its implementation.
Cristina Pimenta, Claudio G. Mann, Brenda Hoagland, Eduardo Carvalheira, Cristina Jalil, Marcos Benedetti, Nilo Fernandes, Carolina Coutinho, Emilia M. Jalil, Mayara Secco Torres Silva, Roberta Trefiglio, Alessandro Farias, Maria Paula G. Mourão, José Valdez Madruga, Josué N. deLima, Ronaldo Zonta, Gabrielle O'Malley, Valdilea G. Veloso, Beatriz Grinsztejn, Thiago S. Torres, for the ImPrEP CAB‐Brasil Study   +20 more
doaj   +1 more source

From protease inhibitors to integrase strand transfer inhibitors: the evolution of HIV drug resistance management

Zhongguo linchuang yanjiu
Antiretroviral therapy (ART) has significantly improved the prognosis of HIV/AIDS patients and has become an important global strategy for the prevention and control of AIDS.
HU Zhiliang, YANG Yongfeng
doaj   +1 more source

Predicting drug-drug interactions between rifampicin and long-acting cabotegravir and rilpivirine using physiologically based pharmacokinetic modeling [PDF]

, 2019
Background. Cabotegravir and rilpivirine are 2 long-acting (LA) antiretrovirals that can be administered intramuscularly; their interaction with rifampicin, a first-line antituberculosis agent, has not been investigated.
Flexner, C, Owen, A, Rajoli, RKR, Curley, P, Siccardi, M, Chiong, J, Back, D   +6 more
core   +1 more source

Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis

, 2022
Declarations Funding The preparation of this review was not supported by any external funding. Authorship and Conflict of interest Hannah Blair is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of ...
Hannah A. Blair (13864794)
core   +1 more source